Gui-Lin Peng1, Ya-Lan Tao2, Qi-Nian Wu3, Yu Zhang4, Jian-Xing He1. 1. The First Clinical College, Southern Medical University, Guangzhou 510515, China;; Department of Thoracic Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; 2. Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China ; 3. Department of Pathology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 4. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Abstract
BACKGROUND: Chromosome 9 open reading frame 86 (C9orf86) is a novel subfamily of GTPases. Previous studies have implicated C9orf86 as a potential oncogene. METHODS: C9orf86 expression was detected in non-small cell lung cancer (NSCLC) cell lines and human bronchial epithelial (16HBE) cell lines by RT-PCR and western blotting. Immunohistochemistry (IHC) was used to detect 180 consecutive NSCLC specimens and 16 normal lung tissues. The correlation between C9orf86 expression and clinicopathological parameters was evaluated. Kaplan-Meier survival analysis and Cox hazards ratio models were used to estimate the effect of C9orf86 expression on survival. RESULTS: C9orf86 was expressed in the cytoplasm in 74 of 180 (41.11%) NSCLC specimens. In clinical pathology analysis, C9orf86 expression significantly correlated with lymph node metastasis and clinical stage significantly (P<0.05). Multivariable analysis confirmed that C9orf86 expression increased the risk of death after adjusting for other clinicopathological factors (P<0.01). Overall survival (OS) and disease-free survival (DFS) were significantly prolonged in the C9orf86 negative group compared to the C9orf86 positive group (P<0.001). Adjuvant chemotherapy prolonged OS and DFS in resected NSCLC patients with C9orf86 negative expression (P<0.001) but not C9orf86 positive. CONCLUSIONS: Positive expression of C9orf86 is an independent prognostic factor for NSCLC patients, and C9orf86 may serve as a prognostic biomarker for patients with NSCLC.
BACKGROUND: Chromosome 9 open reading frame 86 (C9orf86) is a novel subfamily of GTPases. Previous studies have implicated C9orf86 as a potential oncogene. METHODS:C9orf86 expression was detected in non-small cell lung cancer (NSCLC) cell lines and human bronchial epithelial (16HBE) cell lines by RT-PCR and western blotting. Immunohistochemistry (IHC) was used to detect 180 consecutive NSCLC specimens and 16 normal lung tissues. The correlation between C9orf86 expression and clinicopathological parameters was evaluated. Kaplan-Meier survival analysis and Cox hazards ratio models were used to estimate the effect of C9orf86 expression on survival. RESULTS:C9orf86 was expressed in the cytoplasm in 74 of 180 (41.11%) NSCLC specimens. In clinical pathology analysis, C9orf86 expression significantly correlated with lymph node metastasis and clinical stage significantly (P<0.05). Multivariable analysis confirmed that C9orf86 expression increased the risk of death after adjusting for other clinicopathological factors (P<0.01). Overall survival (OS) and disease-free survival (DFS) were significantly prolonged in the C9orf86 negative group compared to the C9orf86 positive group (P<0.001). Adjuvant chemotherapy prolonged OS and DFS in resected NSCLCpatients with C9orf86 negative expression (P<0.001) but not C9orf86 positive. CONCLUSIONS: Positive expression of C9orf86 is an independent prognostic factor for NSCLCpatients, and C9orf86 may serve as a prognostic biomarker for patients with NSCLC.
Entities:
Keywords:
Chromosome 9 open reading frame 86 (C9orf86); immunohistochemistry (IHC); non-small cell lung cancer (NSCLC); prognostic biomarker
Authors: A Schnelzer; D Prechtel; U Knaus; K Dehne; M Gerhard; H Graeff; N Harbeck; M Schmitt; E Lengyel Journal: Oncogene Date: 2000-06-15 Impact factor: 9.867
Authors: David S Ettinger; Wallace Akerley; Hossein Borghaei; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Stefan C Grant; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Feng-Ming Spring Kong; Mark G Kris; Lee M Krug; Rudy P Lackner; Inga T Lennes; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Mary C Pinder-Schenck; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Douglas E Wood; Stephen C Yang; Kristina Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2013-06-01 Impact factor: 11.908
Authors: Chandra K Maharjan; Po Hien Ear; Catherine G Tran; James R Howe; Chandrikha Chandrasekharan; Dawn E Quelle Journal: Cancers (Basel) Date: 2021-10-12 Impact factor: 6.639
Authors: Jordan L Kohlmeyer; Courtney A Kaemmer; Joshua J Lingo; Ellen Voigt; Mariah R Leidinger; Gavin R McGivney; Amanda Scherer; Stacia L Koppenhafer; David J Gordon; Patrick Breheny; David K Meyerholz; Munir R Tanas; Rebecca D Dodd; Dawn E Quelle Journal: Neurooncol Adv Date: 2022-04-09